» Articles » PMID: 18424711

Regulatory T Cells Inhibit Dendritic Cells by Lymphocyte Activation Gene-3 Engagement of MHC Class II

Overview
Journal J Immunol
Date 2008 Apr 22
PMID 18424711
Citations 237
Authors
Affiliations
Soon will be listed here.
Abstract

Lymphocyte activation gene-3 (LAG-3) is a CD4-related transmembrane protein expressed by regulatory T cells that binds MHC II on APCs. It is shown in this study that during Treg:DC interactions, LAG-3 engagement with MHC class II inhibits DC activation. MHC II cross-linking by agonistic Abs induces an ITAM-mediated inhibitory signaling pathway, involving FcgammaRgamma and ERK-mediated recruitment of SHP-1 that suppresses dendritic cell maturation and immunostimulatory capacity. These data reveal a novel ITAM-mediated inhibitory signaling pathway in DCs triggered by MHC II engagement of LAG-3, providing a molecular mechanism in which regulatory T cells may suppress via modulating DC function.

Citing Articles

Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer: Beyond PD-1/PD-L1 Monoclonal Antibodies.

Roussot N, Kaderbhai C, Ghiringhelli F Cancers (Basel). 2025; 17(5).

PMID: 40075753 PMC: 11898530. DOI: 10.3390/cancers17050906.


Bone marrow immune cells and drug resistance in acute myeloid leukemia.

Zhang M, Yang Y, Liu J, Guo L, Guo Q, Liu W Exp Biol Med (Maywood). 2025; 250:10235.

PMID: 40008144 PMC: 11851207. DOI: 10.3389/ebm.2025.10235.


Nanobodies as innovative immune checkpoint modulators: advancing cancer immunotherapy.

Hosseininejad-Chafi M, Eftekhari Z, Oghalaie A, Behdani M, Sotoudeh N, Kazemi-Lomedasht F Med Oncol. 2024; 42(1):36.

PMID: 39719469 DOI: 10.1007/s12032-024-02588-y.


CD137-expressing regulatory T cells in cancer and autoimmune diseases.

Lee K, Mei Y, Liu H, Schwarz H Mol Ther. 2024; 33(1):51-70.

PMID: 39668561 PMC: 11764688. DOI: 10.1016/j.ymthe.2024.12.010.


Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials.

Ren K, Hamdy H, Meyiah A, Elkord E Front Immunol. 2024; 15():1501613.

PMID: 39660130 PMC: 11628531. DOI: 10.3389/fimmu.2024.1501613.